Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation

Although immune checkpoint blockers have yielded significant clinical benefits in patients with different malignancies, the efficacy of these therapies is still limited. Here, we show that disruption of transmembrane protein 176B (TMEM176B) contributes to CD8(+) T cell-mediated tumor growth inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Segovia, Mercedes, Russo, Sofia, Jeldres, Mathias, Mahmoud, Yamil D., Perez, Valentina, Duhalde, Maite, Charnet, Pierre, Rousset, Matthieu, Victoria, Sabina, Veigas, Florencia, Louvet, Cédric, Vanhove, Bernard, Floto, R. Andrés, Anegon, Ignacio, Cuturi, Maria Cristina, Girotti, M. Romina, Rabinovich, Gabriel A., Hill, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521897/
https://www.ncbi.nlm.nih.gov/pubmed/31085177
http://dx.doi.org/10.1016/j.ccell.2019.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521897/
https://www.ncbi.nlm.nih.gov/pubmed/31085177
http://dx.doi.org/10.1016/j.ccell.2019.04.003

Ejemplares similares